Here's How Biotech Company Quantgene Plans to Extend Human Life by 10 Years Within a Decade

Rachel Uranga

Rachel Uranga is dot.LA's Managing Editor, News. She is a former Mexico-based market correspondent at Reuters and has worked for several Southern California news outlets, including the Los Angeles Business Journal and the Los Angeles Daily News. She has covered everything from IPOs to immigration. Uranga is a graduate of the Columbia School of Journalism and California State University Northridge. A Los Angeles native, she lives with her husband, son and their felines.

quantgene

Jo Bhakdi thinks he can extend life with data.

Over the past years, the trained economist and co-founder of Quantgene has helped create a blood test that screens for early signs of some of the deadliest cancers, using millions of culled data points.

"We have a bigger vision behind this," Bhakdi said. "It's what I call decades in a decade — to extend the average human lifespan by ten years in the next ten years."


Quantgene has been developing so-called "liquid test" that can pinpoint the origin of multiple types of cancer by identifying their cellular mutations using artificial intelligence analytics and big data.

The project began five years ago at a U.C. Berkeley lab. Bhakdi partnered with co-founder Monika Hagen to create a system that would screen cancer using algorithms.

Late this year, Bhakdi and Hagen expect to roll out an early cancer screening subscription plan to consumers for an annual cost of around $2,200, pending regulatory approval. And they specifically came to Los Angeles, an image-conscious city that's embraced the idea of wellness, to launch it.

Blood tests are not a new technology for cancer screening, but Quantgene and others are trying to create a more precise tool to identify cancer in its earliest stages by finding mutation patterns that point to the disease. And in the process lower cancer death rates in the U.S.. This year, an estimated 600,000 people will die of the disease. Another 1.6 million will get the grim diagnosis. It's the second biggest killer of Americans year in and year out.

Most blood tests are currently used when doctors already know where the cancer exists, mostly in order to track its progression.

Quantgene founders Jo Bhakdi and Monika Hagen

The new tests examine fragments of DNA that break loose in the bloodstream. Quantgene looks at the different mutations of these cells to identify patterns that signal early forms of cancer or other diseases. The company plans to sell the system as part of a line of tiered-price testing called "Serenity" that includes genetic counseling and profiles.

Quantgene is branding the complex sequencing and AI process that analyzes these mutations the "Griffin Deep Genomics Platform." The company has raised more than $13 million, and expects to raise a Series B round this fall. Bhakdi believes it could upend how people test for cancer. But it has competition.

Amazon-backed, Menlo Park-based Grail Inc. has raised nearly $2 billion. In March, the Silicon Valley company released a report that said it could detect 50 types of cancer across all stages, with a false-positive rate below 1%. The company said it can find its location with 93% accuracy. But finding early-stage cancer — the type that actually save lives — has proven elusive.

Of the 12 deadly cancer types that make up 63% of deaths in the U.S., Grail reported a detection rate of 67% for stages one to three. The company's test is expected to be available within 12 months. A spokeswoman said in an email, it's "too early to comment on cost, however, our principal goal is to ensure broad access to our test, and we hope to make this ground breaking technology available to as many people as possible." Investors include Bill Gates, Bristol-Myers Squibb and Merck.

"The problem with a lot of these liquid biopsy technologies right now — Grail and others — is that they are not really good at detecting cancers at the earliest stages. Because there just isn't that much tumor material in the blood," said Timothy Rebbeck, director of the Zhu Family Center for Global Cancer Prevention at Harvard. "So, it's not to say that it couldn't be done. It's just the right now the technology is not refined enough to do it that really well."

Getting to Cancer Screening at Earlier Stages

For the last few decades, physicians have screened individual organs for signs of cancer, trying to suss out whether a patient has a cancerous growth on the pancreas or breast or lung. These early screenings, coupled with advances in cancer treatments, have been credited with a decline in U.S. deaths related to cancer.

"The median point of diagnosis in these 1.6 million is between stage three and stage four.

If you can shift that point of stage two and one, you would be saving 400,000 people a year," Bhakdi said. "That's crazy if you think about that."

Bhakdi, who comes from a family of scientists and doctors, began the search less than a month before his own mother was diagnosed with stage four colon cancer.

At the time, a family member asked his help in solving a genomic question about whether one could determine if a random, isolated cell was cancer. The answer is very difficult to get. It lays in sequencing the cell's DNA and then comparing it to thousands of others. That ability to compare cells with a massive data trove is now at the heart of their company.

A flow cell used for deep-sequencing produces 6 billion data points per patient sample.Courtesy Quantgene

Bhakdi believes it would have saved his mother.

"If you are diagnosed with colon cancer at stage one, you have a 94% survival rate," he said. "In stage four, you have an 11% survival rate."

Sidestepping Insurers in Santa Monica

One of the best ways to bring down deaths is to diagnose cancer early, said Rebbeck. But even when these technologies are developed for widespread use they could exacerbate disparities for the poor, underserved and uninsured. That's because there remains systemic hurdles of access and cost.

Bhakdi said he understands those concerns. He had hoped originally to work with insurers to get the product out, but they required long-term economic studies to prove they would lower costs. Unable to produce that quickly, Quantgene moved to Santa Monica last year.

"We asked the question, 'What region has the most innovation-driven and future-oriented consumers and physicians and health care experts that are most likely to adopt new technologies?'," he said. "And what we found was very clear, very clear: Los Angeles."

In short, people in Los Angeles pay well to be healthy and beautiful. He pointed to companies that thrive in the metropolis like Next Health, a self-described longevity center that offers cryotherapy, or Remedy Place, a social wellness club.

"There's a big population here, a lot of whom are focused on health and wellness and are willing to spend the money," said David Whelan, chief executive of BioScienceLA, "The Goop effect sort of worked here. This is the place to be able to get a lot of customers very quickly when you're charging a high price point for customized service."

Beyond that, Bhakdi said there's also an extreme level of excellence in clinical infrastructure from medical institutions at UCLA, USC, City of Hope and Cedars-Sinai.

The move, he said, will hopefully allow Quantgene to demonstrate the product's value and convince insurers to offer it, eventually getting it into more people's hands. At the same time, the cost should draw down.

By 2024, the marketplace for personalized medicine and testing is expected to hit $85 billion, according to Pitchbook.

How does it work?

The company uses what's called cell-free DNA in the bloodstream to look for somatic mutations, those that are unrelated to hereditary factors and indicate a cancer growth.

"It's not a black and white thing," Bhakdi said.

It's more like matching different cancer profiles via machine learning. Using algorithms, the company traces the mutation patterns and compares those patterns to others who have the disease. By comparing the patient's mutation pattern along with their profile, Quantgene determines whether a specific cancer is maturing and tries to spot it.

"What the report does is not tell you whether you have cancer or not. That would be irresponsible," Bhakdi said. "It looks into the mutation pattern of the DNA that is in your gut — which means all the DNA that comes from, say, the diet in your body — and it takes these patterns and gives you a very high-resolution insight into how this compares with people with... all other kinds of medical conditions, including the ten leading cancers."

In 2016, Quantgene launched a clinical trial that will help them determine the sensitivity and specificity of the tests. Their goal is to have 10,000 patient blood samples. So far the company has about 5,000.

quantgeneQuantgene has developed a custom assay for DNA extractionCourtesy of Quantgene

But those working with the company think once it comes to market, it could be a game changer, helping physicians figure out how to deal with early signs of cancer.

"A lot of the companies working in molecular diagnostics don't have a good approach to telling physicians what to do and helping out with decision making. Quantgene has come to understand that that aspect of integrating clinical information and then providing guidance on what to do based on probabilities is helpful and necessary," said Jorge Nieva, an advisor to the company and an oncologist and associate professor at the University of Southern California Keck School of Medicine. "It has the real potential to revolutionize the field of cancer screening because our approach to cancer screening up to this point has really been organ-based."

What distinguishes the company, he said, is they are largely driven by math instead of biology.

"With the large database that Quantgene has built of some 40,000 tumors across 15 different cancers types, you can begin to build those patterns so that you can map those genetic abnormalities back to the anatomy," Nieva said.

https://twitter.com/racheluranga
rachel@dot.la
California Passes Landmark AI Law as Russell Westbrook Backs Eazewell

🔦 Spotlight

Good Morning Los Angeles,

What do a new California law and Russell Westbrook’s latest startup have in common? AI at its most powerful and most personal.

California has officially passed the nation’s first AI safety law (SB 53). Signed by Governor Gavin Newsom, the measure requires companies developing large scale AI models to disclose risk assessments and safety testing. On the surface, it sounds procedural. But in practice, it is a potential reset on how quickly AI companies ship new products. For years, the narrative has been “innovation first, oversight later.” With this law, California is betting that transparency can move in tandem with progress. Whether it becomes a model for federal policy or a cautionary tale depends on how the industry responds.

Meanwhile, Eazewell, a newly launched startup co-founded by NBA All Star Russell Westbrook, is tackling one of the most difficult spaces in tech: end of life planning. The company offers an AI platform designed to guide families through complex care transitions. It is not the kind of space most founders rush into. It is emotional, often uncomfortable, and full of fragmented systems. But precisely because of that, the potential impact is significant. By blending AI with healthcare navigation, Eazewell is aiming to make one of life’s hardest processes less overwhelming. Westbrook’s involvement draws attention, but the real story is a startup willing to bring technology into conversations many people would rather avoid.

Taken together, these stories capture the stretch of AI right now. On one end, lawmakers are moving to contain its risks. On the other, founders are pushing it into the most intimate corners of our lives. It is not often that state legislation and end of life care land in the same conversation, but that is the reality of AI in 2025.

🤝 Venture Deals

      LA Companies

      • Midi Health raised $50M in a Series C round led by Advance Venture Partners. The women’s health startup, which focuses on perimenopause, menopause, and midlife care, claims a $150 million revenue run rate and is now building its own AI powered search engine tailored for women’s health. The funding will support scaling operations, expanding the longevity and care services it offers, and investing in AI and infrastructure to advance its platform. - learn more
      • PINC Technologies, a Caltech spinout, announced a $6.8M Seed+ round led by Quantonation, with backing from investors including Wilson Hill Ventures, Freeflow Ventures, Hamamatsu Ventures, Qubits Ventures, Santec, and the Caltech Seed Fund. The company develops integrated nonlinear photonic devices and circuits aimed at making scalable nonlinear photonics practical for real-world applications. The funding will be used to accelerate commercialization, scale the team, and bring the technology built in Caltech’s Nonlinear Photonics Lab into broader markets. - learn more
      • Swan announced a Series C financing to support the launch of Swan International, expanding its concierge Bitcoin wealth services globally under U.S.-regulated custody. The company also added a Head of Private Wealth to its team to lead this expansion into new markets. This move aims to position Swan as a high-touch, cross-border wealth platform anchored in crypto. - learn more
      • Vatom announced a strategic investment led by the Hilton Family Office, supporting its mission to power next-generation digital finance engagement. The funding will help Vatom deepen its infrastructure for tokenized assets, NFTs, and blockchain experiences across Web3 ecosystems. This injection positions the company to expand its reach and build tools that make digital finance more immersive and user-centric. - learn more

      LA Venture Funds

      • Powerhouse Capital led a growth funding round for Five Iron Golf UAE’s franchisees, backed by a network of investors and professional athletes. The capital is targeted to fuel expansion, new venues, and enhanced operations across the UAE market. This investment reflects confidence in pairing tech-driven sports entertainment with scalable hospitality models. - learn more
      • MTech Capital remains a backer as CyberCube announces a fresh infusion of more than $180M led by Spectrum Equity. The cyber risk analytics firm is using the capital to accelerate product innovation, expand globally, and deepen its presence across insurance, reinsurance, and broking markets. The investment will help CyberCube scale solutions that quantify cyber risk at portfolio levels and power smarter underwriting decisions. - learn more
      • Helena participated in Phaidra’s $50M Series B round, joining lead investor Collaborative Fund and backers like Index Ventures and NVIDIA. Phaidra builds AI systems to optimize energy, cooling, and operational efficiency in data centers, striving to help infrastructure run smarter. The new funding will be used to scale its platform, deepen customer deployments, and expand its reach in facility control and AI automation. - learn more
      • Lasagna joined DeepWork Capital, Florida Opportunity Fund, and Lookout Ventures in backing Circuitry.ai’s seed financing round. Circuitry.ai offers a Decision Intelligence platform that powers “Autonomous Service Journeys” for manufacturers, layering AI advisors, agents, and analytics to optimize service operations. The funding will help scale engineering and go-to-market teams, deepen integrations with service platforms, and expand the solution across industries like automotive, industrial systems, and medical devices. - learn more
      • B Capital led a $64M seed round in Axiom Math, the startup founded by a Stanford dropout aiming to build an AI system that not only solves the hardest math problems, but also invents new ones. Axiom has pulled talent from top places like Meta to push toward next-gen mathematical reasoning. The funds will support scaling research, expanding the team, and accelerating their vision of AI that thinks deeper in pure and applied math. - learn more
      • Alexandria Venture Investments and Wedbush Healthcare Partners joined the $205M capital raise for Crystalys Therapeutics, which emerged from stealth mode to fund late-stage trials of its gout treatment. The San Diego based biotech is pushing forward dotinurad, a once-daily oral drug being tested across U.S. and European trials for patients who don’t respond to first-line therapies. With this backing, Crystalys aims to fast-track clinical development and bring a needed second-line gout treatment to market. - learn more
      • GordonMD Global Investments joined new and existing backers in Star Therapeutics’ oversubscribed $125M Series D financing round. The biotech, co-led by Sanofi Ventures and Viking Global, is deploying the capital to push forward its lead program VGA039, a monoclonal antibody targeting bleeding disorders. The funds will help accelerate its clinical trials and advance its pipeline toward commercialization. - learn more
      • Hawke Ventures joined a funding round in Tie, which raised $10M in Series A to support its AI identity platform for e-commerce brands. Tie helps retailers reclaim hidden website visitors by identifying and enriching anonymous traffic to build better marketing audiences. The capital will go toward scaling the team, deepening integrations with commerce and marketing stacks, and expanding reach among D2C brands. - learn more
      • Foxhog Ventures led a ₹44.37 crore (~$5.3M USD) seed investment in Assessli, a Kolkata deep-tech startup developing what it calls “Large Behavioural Models” (LBMs) that combine genomics, psychology, and digital life data into highly personalized AI twins. The funding will support Assessli’s expansion into the U.S. and U.K., accelerate product commercialization, and increase its technical hiring to scale out its platform. - learn more
      • Bonfire Ventures participated in Alvys’ $40M Series B round, alongside RTP Global, Alpha Square Group, Titanium Ventures, Picus Capital, and others. Alvys offers an AI powered transportation management system (TMS) that streamlines freight operations including dispatch, load management, billing and analytics by automating workflows and integrating across platforms. The funding will help the company build out enterprise features, scale engineering, deepen integrations, and accelerate growth in the logistics and freight sector. - learn more
      • M13 participated in an $11M Series A round for Anything, an AI platform that turns natural-language prompts into production-ready mobile and web applications. Rather than just generating prototypes, Anything’s backend includes infrastructure like authentication, payments, and storage under the hood. With this funding, the company will scale development, expand its user base (now over 700,000), and deepen its platform capabilities to support full app deployment. - learn more
      • Halogen Ventures closed a $30M Fund III and has committed to invest in early stage startups in Alabama, becoming the first out of state VC to partner with Innovate Alabama’s InvestAL program. They have already begun deploying capital into the state, backing startups like Moxi, Auditocity and Croux, and are actively running pitch events to build a local pipeline. - learn more

      LA Exits

      • Griffin Club has been acquired by Bay Club, deepening Bay Club’s footprint in Los Angeles. Griffin Club is a legacy athletic, aquatic, and social club in West LA, known for features like tennis and pickleball courts, pools, wellness classes, and high-end amenities. Bay Club intends to bring Griffin into its LA campus and integrate it into its broader network of fitness and lifestyle clubs. - learn more
      • Beverly Hills Rejuvenation Center has been acquired by Motivant, with Sarah Gabriel installed as its new CEO. The deal brings the med spa franchise into Motivant’s portfolio, aligning it with a growth-focused investment platform. Gabriel’s appointment signals a strategic push to leverage new leadership and scale operations under Motivant’s guidance. - learn more

            Download the dot.LA App

            Salt AI Secures $10M to Untangle Healthcare’s Toughest Workflows

            🔦 Spotlight

            Hello Los Angeles,

            Not every startup raise deserves the spotlight, but this week’s news from Salt AI is worth paying attention to. The LA based company just closed a $10 million round led by Morpheus Ventures with participation from Struck Capital, Marbruck Investments and CoreWeave. The goal is to expand what it calls “contextual AI,” and if it works, it could quietly change how some of the most complex corners of healthcare get untangled.

            Healthcare is notorious for slow, clunky systems. Even the smallest workflow, like drug trial data, clinical documentation, or compliance reviews, can drag on for weeks because the tools were never built for speed. Salt AI is betting that the fix is not flashy consumer apps or billion parameter models, but something more practical: AI that slots directly into the day to day grind of life sciences. Their platform lets non technical teams visually build and deploy workflows that would normally take months of coding. Drag, drop, done.

            It sounds simple, but the implications are not. Imagine a biopharma team testing a new drug, able to cut through compliance hurdles in days instead of months. Or clinical researchers spinning up experiments and seeing usable results in real time. Salt AI’s pitch is not about replacing scientists, it is about giving them back time in an industry where time can literally mean lives.

            The new capital will help scale engineering, grow its customer footprint, and push further into healthcare and biopharma. But more importantly, it gives Salt AI the chance to prove that “contextual AI” is more than a buzzword. If they succeed, the company will not just chip away at bottlenecks, it could reshape how innovation itself moves through one of the world’s most heavily regulated and mission critical industries.

            🤝 Venture Deals

                LA Companies

                • Bonsai Health raised $7M in a seed round led by Bonfire Ventures and Wonder Ventures. The Santa Monica based company builds an agentic AI platform that automates front office healthcare workflows, things like patient outreach, scheduling and clinical follow-ups, working behind the scenes to keep patients connected to care and reduce administrative burden. It plans to use the funding to accelerate its specialty AI agents, expand into new medical specialties, and scale its commercialization nationwide. - learn more
                • Genstore raised a $10M Seed round led by Weimob, with participation from Lighthouse Founders’ Fund. The Los Angeles based startup is building an AI-native e-commerce platform that lets merchants launch and run online stores using conversational prompts, automating everything from product listings and copywriting to customer service. The funds will go toward accelerating product development, expanding into new markets, and refining features that simplify online commerce for small and midsized sellers. - learn more
                • TransAstra secured a $5M investment to scale its asteroid capture technology in partnership with NASA. The company aims to advance systems that can snag and repurpose small bodies in space, contributing to sustainable space infrastructure and debris mitigation. With this funding, TransAstra will expand development, deepen its relationship with NASA, and accelerate deployment of its capture hardware. - learn more

                LA Venture Funds

                • Fika Ventures led a seed round investing in MaxHome, joining BBG Ventures, Four Acres and 1Sharpe Ventures. MaxHome is building an AI-native platform focused on automating real estate transaction coordination, the messy, manual work that slows deals. Fika backed the team because it sees a huge opportunity in streamlining broker workflows, reducing errors, and improving the experience for agents and homebuyers alike. - learn more
                • MANTIS Ventures joined NEA, Sequoia, NVIDIA, J.P. Morgan and others in leading a $50M Series B for Factory, valuing the AI coding company at $300 million. Factory builds “droids,” AI agents that automate software development tasks across environments, and claims their platform now tops the Terminal Bench benchmark. With this capital, Factory aims to expand enterprise adoption, deepen integrations, and scale its engineering team globally. - learn more
                • SafeHill (formerly Tacticly) announced a $2.6M pre-seed round led by Mucker Capital, with participation from Chingona Ventures, Techstars, Chicago Early Growth Ventures, The Source Groups, and others. The Chicago-based cybersecurity startup is launching from stealth with SecureIQ, a continuous Threat Exposure Management platform that blends AI-driven testing with human validation to help organizations find and shore up attack paths. The funding will be used to expand engineering, enhance AI-assisted ethical hacking, deepen enterprise partnerships, and broaden compliance and monitoring capabilities. - learn more
                • Prototype Capital was among the investors in Nilo Technologies’ $4M seed round, alongside backers like Supercell, a16z Speedrun, KFund, and Flex Capital. Nilo is building an AI native 3D creation platform that makes game development more accessible, letting creators build interactive worlds in their browser without complex tooling. The funding will help accelerate product development, bring in more users as “Founding Builders,” and expand the platform’s capabilities for real time, multiplayer creation. - learn more
                • Rebel Fund participated in a $7.5M funding round for Indian fintech Gold Firm Gullak backed by Y Combinator. Gullak offers digital gold savings and lending solutions targeted at underbanked consumers in India. Rebel Fund’s investment will help Gullak scale operations, deepen financial inclusion, and expand its product offerings. - learn more
                • B Capital joined Wellington Management, General Catalyst and others in a $400M funding round for Capital Rx, which is rebranding as Judi Health. The company, which operates a pharmacy benefits management platform, will use the capital to expand into full-spectrum health benefits, integrating medical, dental and vision claims processing with its existing PBM capabilities. The move positions Judi Health as a unified tech backbone for benefits administration across employer and plan clients. - learn more
                • Supply Change Capital joined a seed funding round that raised $4.7M for Helios AI, a startup building the first AI co-pilot for food and agriculture supply chains. Helios’ platform combines climate modeling, commodity forecasting, and real-time data to help buyers and suppliers make smarter decisions in volatile markets. The funding will be used to scale the product, expand data coverage globally, and bring its AI tools to more players across the agri-food sector. - learn more

                    Download the dot.LA App

                    ServiceTitan Ups the AI Stakes

                    🔦 Spotlight

                    Hello Los Angeles,

                    ServiceTitan is making it clear: the trades are getting a tech glow up. At its annual Pantheon conference in Glendale, the home services software giant rolled out a bold AI vision and topped it off with a fresh acquisition that could change the way HVAC contractors do business.

                    First, the AI. ServiceTitan unveiled what it calls the “next evolution” of its platform, and this is not just window dressing. Think automated call summaries so techs spend less time typing, predictive scheduling that knows when your AC is likely to fail before you do, and estimates that generate faster than a homeowner can ask, “So, how much is this going to cost me?” For small and mid sized contractors, these are the kinds of tools that level the playing field against the big chains and maybe even help them get home before dinner. It is AI built not for hype, but for the day to day grind of the trades, where minutes saved can mean jobs won and customers kept.

                    Then came the news that ServiceTitan is acquiring Conduit Tech, a Boston startup best known for its LiDAR powered HVAC design software. Instead of squinting at tape measures and crunching numbers in clunky spreadsheets, contractors can now scan a home, generate a 3D model, and deliver a polished, ACCA certified proposal on the spot. Translation: faster bids, more trust, and fewer “I will get back to you next week” moments.

                    Put together, the AI rollout and Conduit deal are more than product updates. They are a signal of where ServiceTitan wants to take the industry. This is not just software that keeps the books balanced or trucks dispatched. It is an attempt to make technology an advantage in a field where labor is scarce, expectations are high, and every interaction with a customer matters. In short, ServiceTitan is not just keeping the lights on, it is rewiring how the trades get work done.

                    🤝 Venture Deals

                        LA Companies

                        • Modern Animal has hit a $100M annual run rate and closed a new $46M funding round led by Addition, True Ventures and Upfront Ventures with participation from Founders Fund. The company delivers veterinary care both in clinics and virtually, and it is using the funds to expand services such as specialty care, 24/7 virtual access, integrated pharmacy and ecommerce, along with extended urgent care hours. The company also announced a board expansion with new leadership added to support scaling operations and enhancing its technology infrastructure. - learn more
                        • MarqVision raised a $48M Series B round led by Peak XV Partners, with participation from investors including Salesforce Ventures, HSG, Coral Capital, and returning backers like Y Combinator and Altos Ventures. Based in Los Angeles, MarqVision offers AI-powered brand protection tools—monitoring marketplaces, removing counterfeit listings, managing trademarks, and protecting brand reputation online. The new funds will go toward expanding its AI and engineering teams, accelerating automation, enabling enterprise-grade features, and growing its global presence in markets like Japan, Korea, China, Europe and beyond. - learn more
                        • Divergent Technologies raised $290M in a Series E round led by Rochefort Asset Management, with $250M in equity and $40M in debt, bringing its valuation to about $2.3 billion. Using its proprietary DAPS (Divergent Adaptive Production System) platform, the Torrance based company builds hardware for aerospace, defense and automotive sectors by combining rapid design, additive manufacturing and automated assembly. The new capital will help Divergent scale its manufacturing capacity, build out its team and develop new capabilities for upcoming product lines. - learn more
                        • Apex raised $200M in a Series D round led by Interlagos, giving the Los Angeles company a valuation above $1 billion. Apex builds configurable “satellite bus” platforms used by commercial and government clients, including for communications, sensing, and national security constellations. The capital will boost production capacity by 50 percent, expand its manufacturing footprint in Los Angeles, and strengthen vertical integration including acquiring propulsion technology and insourcing more subsystems. - learn more

                          LA Venture Funds

                          • Mantis Venture Capital joined Benchmark, Uncork, Y Combinator and Mayfield in backing Numeral’s $35M Series B, part of a $57M total funding haul. Numeral is an AI powered platform that automates everything around sales tax for e-commerce and SaaS brands including filing, remittance, exemption certificates, state registrations, nexus detection and more. The money will go to speeding up product innovation, building out its global compliance footprint, and adding smarter automation so finance teams can stop wrestling with tax rules and start scaling. - learn more
                          • Magnify Ventures participated in Series A for Seven Starling, contributing to an $8M funding round led by Rethink Impact. Seven Starling is a virtual women’s mental health company focused on maternal mental health, offering group therapy, medication management, patient advocates, and digital tools. The new capital will fuel its expansion into more U.S. states (aiming for over 30 by the end of 2026), deepen partnerships with healthcare providers, and scale its model to help more mothers. - learn more
                          • Calibrate Ventures led Vibranium Labs’ $4.6M seed round, joined by Mirae Asset and investors including a16z and Franklin Templeton. Vibranium Labs’ flagship product, “Vibe AI,” acts as a full-time AI incident engineer, monitoring, triaging, and resolving IT incidents automatically. The funds will be used to expand the engineering team, accelerate product development, and deepen integrations so Vibe AI can be embedded into more incident response systems across industries. - learn more
                          • B Capital led a $20M financing round in Extend, with additional participation by March Capital, Point72 Ventures, FinTech Collective, and Commerce Ventures. Extend, a spend-and-expense management platform, allows businesses to use virtual cards with their existing bank or card programs while offering workflow tools like receipt capture, approvals, and automated reconciliation. The new capital will help Extend scale issuer partnerships, launch new expense management services, accelerate its path to profitability, and the company also added Francois Horikawa as CFO to help guide the financial strategy forward. - learn more
                          • Alexandria Venture Investments joined Versant Ventures and Qiming Venture Partners USA in a $65M Series A for Dualitas Therapeutics, a South San Francisco company developing bispecific antibodies through its DualScreen discovery engine. Dualitas is advancing two lead programs, DTX-103 for allergic disease and DTX-102 for autoimmune conditions, both showing strong preclinical results. The funding will support these programs and expand the company’s platform to discover new bispecific candidates in immunology, inflammation and beyond. - learn more
                          • Oversubscribed Ventures joined a syndicate that invested in Noble Mobile’s $10 million seed round. Noble Mobile, founded by Andrew Yang, is a telecom startup offering unlimited data plans while giving customers cash back when they use less data. The funds will be used to launch operations, roll out its mobile virtual network service, and build features that encourage better digital wellness. - learn more
                          • Mantis Venture Capital participated in Doctronic’s $20M Series A round, which was led by Lightspeed Venture Partners and also backed by Union Square Ventures, Tusk Ventures, Seven Stars, and others. Doctronic is a healthcare AI startup building a platform for fast, personalized medical advice and virtual visits with licensed physicians, aiming to reduce wait times and costs. The new funds will help the company scale its operations across the U.S., expand partnerships with insurers and health systems, and extend its reach to more patients. - learn more
                          • Strong Ventures led a Series A round investing about ₩1 billion in Ares3, with Seoul National University Technology Holdings also participating. Ares3 runs florist subscription service “Honest Flower” for consumers and “FlowerGo,” a B2B platform for floral suppliers, with steady growth thanks to brand partnerships and solid demand. The new capital will help Ares3 extend its reach via offline experience locations and campaigns to shift public perception of flowers from luxury to everyday goods. - learn more
                          • Gold House Ventures participated in MedSetGo’s oversubscribed $2.4M seed round led by TurboStart. MedSetGo is an AI-driven healthcare company based in San Francisco that is working to streamline patient care transitions by helping people find and schedule the right care after discharge. The funding will go toward accelerating product development and hiring, especially expanding the engineering, data science, and commercialization teams. - learn more
                          • March Capital was among the investors in Lila Sciences’ $235M Series A round, which was co-led by Braidwell and Collective Global. Lila builds an autonomous science platform combining AI, robotics and software to automate the scientific method - generating hypotheses, designing experiments, running them, learning from results. The funds will be used to scale Lila’s “AI Science Factories,” expand globally in cities like Boston, San Francisco and London, and accelerate its ability to explore materials, chemistry, life sciences and diagnostics more quickly. - learn more

                            Download the dot.LA App

                            RELATEDEDITOR'S PICKS
                            Trending